ArticleJournal of neuro-oncology2013
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.Journal of neuro-oncology · 2025Guideline
- Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.Neurologia medico-chirurgica · 2022Pooled it
- Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Oncotarget · 2015Pooled it
- Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.Journal of neuropathology and experimental neurology · 2023Article
- Identification of necroptosis-related genes as prognostic indicators for lower-grade glioma.American journal of cancer research · 2023Article
- A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRI.Diagnostics (Basel, Switzerland) · 2021Article
- Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells.Scientific reports · 2021Article
- The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.Brain pathology (Zurich, Switzerland) · 2021Article
- Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.Journal of neuropathology and experimental neurology · 2019Article
- Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre.Acta neuropathologica communications · 2019Article
- D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification.Diagnostic pathology · 2018Article
- Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.BMC cancer · 2018Article
- Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.Journal of neuro-oncology · 2017Article
- Expression and prognostic value of JAM-A in gliomas.Journal of neuro-oncology · 2017Article
- Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.PloS one · 2017Article
- APNG as a prognostic marker in patients with glioblastoma.PloS one · 2017Article
- The Danish Neuro-Oncology Registry: establishment, completeness and validity.BMC research notes · 2016Article
- Expression and prognostic value of the WEE1 kinase in gliomas.Journal of neuro-oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade gliomas (LGG) have a slow growth rate, but transformations into malignant gliomas with a rapid deterioration occur in many patients. The aim of this study was to evaluate clinical prognostic factors in a population-based cohort of patients with LGG. In addition we investigated the expression and prognostic value of the isocitrate dehydrogenase 1 (IDH1) R132H mutation. Seventy-four patients diagnosed between 2005 and 2009 in the Region of Southern Denmark were identified using the Danish Cancer Register and The Danish Pathology Databank. Survival analysis using Cox regression was performed in 52 patients with tumor samples useable for immunohistochemical evaluation of IDH1 status. Patients with a contrast enhancing tumor, neurological deficits, headache, an astrocytic tumor and PS 2-4 had an increased risk of recurrence. In univariate analysis age > 50 years (HR 2.14, 95 % CI 1.08-4.24), having neurological deficit (HR 2.28, 95 % CI 1.15-4.52), receiving post-surgical treatment (HR 2.52, 95 % CI 1.19-5.32), being in performance status 2-4 (HR 1.44, 95 % CI 1.15-1.81), and having an astrocytic tumor (HR 3.79, 95 % CI 1.64-8.73) were associated with poor survival. Mutated IDH1 (mIDH1) was identified in 46 % of the patients and was significantly correlated to a good survival in both univariate (HR 0.24, 95 % CI 0.11-0.53) and in multivariate analysis (HR 0.40, 95 % CI 0.17-0.91). The other clinical variables were not significant when adjusted for the effect of mIDH1 status. We find that young age, the absence of neurologic deficit, PS 0-1 and oligodendroglial histology were associated with better survival. IDH1 status showed independent prognostic information when adjusting for classical prognostic factors, and should be validated in a larger patient population.
Indexed as
Identifiers
23817809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.